ECP Alzheimer’s Trial Reports Cognitive Gains in 190 Patients
A 12-month, multicentre, randomised, sham-controlled trial studied external counterpulsation (ECP) in 190 people with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s. ECP uses ECG-synchronised pressure cuffs on the legs to boost blood flow toward the heart. Participants received treatment for six months, followed by observation through week 52.
The study reported better average daily-function and cognitive scores in the active-treatment group than in the sham group. Improvements were still evident at week 52. ScienceAlert also reported that about 84% of participants improved during treatment and roughly 75% remained above their starting level six months after treatment ended; these figures were cited from the report and the device company.
The results are preliminary. The trial was funded by Renew Research, had potential conflicts of interest, and used a single-blind design. Participants were selected using clinical criteria rather than biomarker confirmation, and the sham treatment may not have fully concealed group assignment. The device has European certification for this use, but the article says it has not received equivalent FDA approval in the United States. Larger, independent studies are needed to confirm the findings and long-term safety.
Neutral
This medical research has no direct connection to cryptocurrency fundamentals, regulation, adoption, or blockchain activity, so it is unlikely to provide a meaningful trading signal for BTC, ETH, or other digital assets. Short-term crypto prices are more likely to respond to macroeconomic data, interest-rate expectations, ETF flows, regulatory developments, and market positioning. The report could attract attention to healthcare or medical-device companies, but any effect would be limited to those sectors rather than crypto markets.
Similar health-study headlines can generate brief interest in related equities, especially when early results appear promising. However, such moves often depend on follow-up evidence, regulatory decisions, and commercial prospects. Here, funding ties, trial-design limitations, and the lack of equivalent US FDA approval temper the claims. If the findings are independently replicated and lead to broader authorization, they could matter for the medical-device sector over the longer term, but any spillover to crypto would likely be negligible. Overall, the expected impact on crypto trading and market stability is neutral.